Search results for: 'Companion Diagnostic Market size'

The concept of companion diagnostics (CDx) was developed when researchers realized that even potent drugs only had an efficacy between 25% and 60%, the lowest being in oncology. Therefore, a clinical pharmacogenetic assay became important to distinguish patients more likely to respond to a drug or at a lesser risk of associated adverse pathophysiol...

26 Aug 2024  |  Global  |  Market Research

Growth Opportunities in the Tissue Diagnostics Industry, Global, 2024 2029

Companion Diagnostics-specific Advanced Staining and Multiomics Capabilities are Driving Market Growth

Infographics

×

The global tissue diagnostics market will experience significant growth driven by the need for advanced staining in precise biomarker identification in personalized medicine, tissue biopsy test volumes, and pre-analytical and advanced staining platform development. According to the WHO, there will be a 60% rise in cancer cases worldwide by 2040,...

This study aims to cover the regulatory outlook and the diagnostics and drug approval process in the US, Europe, India, China, Japan and Brazil. Comparative analysis enables competitors to understand various regulatory hurdles and to position their products in pipeline better and plan for costs. Comparative analysis also enables an understanding of...

This research service offers a comprehensive analysis of the global oncology biomarker diagnostics market, which has transformed with the convergence of clinical demand, advances in technology, and strategic collaborations/partnerships coupled with precision medicine initiatives. It categorizes the market by technology (omics, immunoassays, bioinfo...

The global clinical diagnostics market is poised for strong growth as stakeholders shift focus toward high-growth segments such as precision medicine, decentralized diagnostics, software-driven solutions, and product expansion. Companies continue to adopt LIMS and other digital platforms while emerging opportunities in the POCT sector further drive...

With the end of the COVID-19 pandemic, healthcare providers have been directing most of their capabilities toward preventive healthcare and precision medicine, as the clinical diagnostics industry continues its transition from a centralized to a decentralized testing model. Globally, 2024 is set to be a profitable year for the industry, which will ...

This research analyzes how point-of-care (PoC) diagnostics is evolving from simple tests to decentralized, connected, and clinically actionable testing platforms across hospitals, outpatient settings, homes, and pharmacies.The study assesses key technology shifts, including rapid molecular testing, lateral flow assays, microfluidics, biosensors, sm...

22 Apr 2024  |  Global  |  Market Research

Global Molecular Diagnostics Market, Forecast to 2029

Molecular Diagnostics Unleash Growth Opportunities, Steering Innovation Personalized Medicine

Infographics

×

The global molecular diagnostic market will experience significant growth due to a broad range of factors, such as increased demand from the COVID-19 pandemic, an increasing number of cancer cases, and the swift evolution of technological capabilities. Technological advancements, such as polymerase chain reaction (PCR), digital PCR, and next-gen...

Clinical diagnostics is undergoing a radical shift, driven by omics integration for precision health, digital diagnostics services, and smart screening solutions. Digital diagnostics are streamlining data analysis and communication, and enhancing overall efficiency. Smart screening, powered by AI and machine learning, is ensuring early and accurate...